Hologic guided for full fiscal 2023 revenue between $3.995 billion and $4.035 billion, from a previous guidance of revenue between $3.925 billion and $4.025 billion.

Hologic, Inc. made $4.08 a share in profit (GAAP) in FY2024 on $4.03 billion in sales. The current analyst firm consensus has earnings bumping up to $4.25 a share in FY2025 as revenues rise to $4 ...

Hologic delivered strong revenue and profitability to start fiscal 2024, exceeding the high-end of our guidance for both the top-line and the bottom-line, says CEO. España. India.

Hologic is expected to post earnings of $1.07 per share for the current quarter, representing a year-over-year change of +0.9%. Over the last 30 days, the Zacks Consensus Estimate has changed -4.6%.

Hologic stock, which had been up narrowly to start the day, was the top performer in the S&P 500. It was on pace for its largest percentage increase since June 22, 2006, when it rose 18%.

Hologic’s HOLX Molecular Diagnostics business posted a 7.8% (excluding COVID-19-related sales) growth in the second quarter of fiscal 2025, although results did not reflect its full potential ...

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Hologic, Inc. HOLX is slated to report first-quarter fiscal 2024 results on Feb 1, after the closing bell. In the last reported quarter, the company’s earnings of 89 cents per share surpassed ...

Medical technology company Hologic reported a higher third-quarter profit on Monday, driven by strong demand for its diagnostics and breast health products, but forecast revenue for the current ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global champion of women’s health, today announced that it has signed a definitive agreement to acquire Gynesonics, Inc ...

Hologic is expected to post earnings of $1.07 per share for the current quarter, representing a year-over-year change of +0.9%. Over the last 30 days, the Zacks Consensus Estimate has changed -4.6%.